Skip to main content
Equibles
NEO logo

NEO · Neogenomics Inc

Track NEO — free Ask ALVIS about NEO
$15.47 +2.06 (+15.32%)
Market Cap
$1.74B
Shares
130.21M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.14 Open$14.00 Day$13.10–14.06 52W$4.72–15.57 Avg vol 30d3.6M Short int13.8M · 10.6% float · 6.0d Short vol54% Last earningsJul 28, 2026 DataJan 2020–Jul 2026 Filing10-Q · Jul 28

Up next

Next earnings call
Oct 27, 2026 Est · unconfirmed · in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 28, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bearish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 18.2 · elevated Equity put/call 0.71
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +23%
above
Price vs 50-day avg +10%
above
RSI (14) 46
neutral
MACD trend Negative
52-week position 78%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Strong
1-month return −4%
trailing
6-month return +9%
trailing
YTD return +12%
this year
Relative strength +3%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $12 › 200d $11 — 50d above 200d
Institutional flow Distributing
52 of 254 funds reported for Jun 30 · net -113.0K sh shares · +10 new
Insider flow Distributing
Net -$59.9K over 90 days · 100% sells
Short interest Rising
10.57% of float · ▲ +18.5% MoM · 6.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
254 holders — near 3-yr low, contrarian setup
Squeeze score 88
high risk · 0–100
Fundamentals
Weak
Revenue growth +10%
Y/Y
Gross margin 43%
contracting
EPS growth −300%
Y/Y
Free cash flow $-21.8M
Balance sheet $182.2M
net debt
Quant / Vol
risk profile
Very High
Volatility 62%
annualized · 1-yr
Max drawdown −46%
past year
ATR 5.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Jul 28, 2026
Consolidated revenue · Updated FY 2026 Guidance Raised $802M – $806M
prior FY $727.33M midpoint +10.5% Y/Y
Net loss · Updated FY 2026 Guidance Initiated $-42M – $-34M
Adjusted EBITDA · Updated FY 2026 Guidance Raised $56M – $58M
Guided vs delivered · last 1 settled
Revenues full year 2025
guided $735M – $745M
$727.33M Miss −1.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+23% Bullish
Price vs 50-day avg
+10% Bullish
RSI (14)
46 Neutral
MACD trend
Negative Bearish
52-week position
78% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $12 › 200d $11 — 50d above 200d
Institutional flow Distributing
52 of 254 funds reported for Jun 30 · net -113.0K sh shares · +10 new
Insider flow Distributing
Net -$59.9K over 90 days · 100% sells
Short interest Rising
10.57% of float · ▲ +18.5% MoM · 6.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
254 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $5 Now $13 · 78% 52-wk high $16
vs 200-day avg +23% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings
Metric Latest Period YoY

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NEO
Neogenomics Inc
this stock
$1.74B +11.7% +10.1% — 10.6%
TMO
Thermo Fisher Scientific Inc.
 $214.21B -0.4% +0.4% 31.7 1.4%
DHR
Danaher Corp /De/
 $139.93B -12.7% +8.5% 35.3 1.4%
IDXX
Idexx Laboratories Inc /De
 $44.93B -15.8% +10.4% 41.9 2.7%
IQV
Iqvia Holdings Inc.
 $40.55B +7.8% +41.6% 30.2 3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
259
% held
97.8%
Reported
52 of 254
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
249
View
Short & Settlement
Short Interest Rising
Shares short
13.8M
Days to cover
6.0d
Change
+2.1M sh
View
Short Volume
Short vol %
54%
As of
Jul 28, 2026
Short Total
View
Fails to Deliver
FTD shares
15.1K
Value
$214.7K
As of
Jun 30, 2026
View
Off-Exchange
Off-exchange %
41.6%
Week of
May 4, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$59.9K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
May 7, 2025
View
Financials
Financials
Net income (FY)
$-108.0M
EPS diluted
$-0.04
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 28, 2026
This year
16
View
Proposed Sales
Value
$59.2K
Shares
5.3K
Filed
Jun 15, 2026
View
Earnings & Events
Earnings Calls
Last call
Jul 28, 2026
View

Performance

5D 20D 120D MTD YTD
NEO -10.1% -4.3% +9.0% -9.9% +11.7%
SPY -0.4% +1.4% +6.3% -1.0% +8.4%
vs SPY -9.7% -5.7% +2.7% -8.9% +3.4%
Key facts CIK 1077183 CUSIP 64049M209 13F (30d) 47 filings 47 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)